MXPA04006575A - Amino carboxamidas sustituidas para el tratamiento de la enfermedad de alzheimer. - Google Patents
Amino carboxamidas sustituidas para el tratamiento de la enfermedad de alzheimer.Info
- Publication number
- MXPA04006575A MXPA04006575A MXPA04006575A MXPA04006575A MXPA04006575A MX PA04006575 A MXPA04006575 A MX PA04006575A MX PA04006575 A MXPA04006575 A MX PA04006575A MX PA04006575 A MXPA04006575 A MX PA04006575A MX PA04006575 A MXPA04006575 A MX PA04006575A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- treatment
- alzheimer
- substituted amino
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se relaciona con compuestos de formula (I) utiles en el tratamiento de enfermedad de Alzheimer y otras enfermedades similares. Estos compuestos incluyen inhibidores de la enzima secretasa b que son utiles en el tratamiento de enfermedad de Alzheimer y otras enfermedades caracterizadas por deposicion del peptido b A en un mamifero. Los compuestos de la invencion son utiles en composiciones farmaceuticas y metodos de tratamiento para reducir la formacion de peptido b A.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34531602P | 2002-01-04 | 2002-01-04 | |
US35041902P | 2002-01-18 | 2002-01-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04006575A true MXPA04006575A (es) | 2004-10-04 |
Family
ID=26994342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04006575A MXPA04006575A (es) | 2002-01-04 | 2004-07-02 | Amino carboxamidas sustituidas para el tratamiento de la enfermedad de alzheimer. |
Country Status (8)
Country | Link |
---|---|
US (1) | US6962934B2 (es) |
EP (1) | EP1458745A2 (es) |
JP (1) | JP2005534614A (es) |
AU (1) | AU2003206413A1 (es) |
BR (1) | BR0306724A (es) |
CA (1) | CA2472617A1 (es) |
MX (1) | MXPA04006575A (es) |
WO (1) | WO2003057721A2 (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004047743A2 (en) * | 2002-11-22 | 2004-06-10 | Bristol-Myers Squibb Company | 1-aryl-2-hydroxyethyl amides as potassium channel openers |
US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
JP2007516207A (ja) * | 2003-06-30 | 2007-06-21 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病の治療のためのN−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤 |
US20070225374A1 (en) * | 2003-10-30 | 2007-09-27 | Elan Pharmaceuticals, Inc. | Hydroxypropyl Amides for the Treatment of Alzheimer's Disease |
EP1697308B1 (en) | 2003-12-19 | 2014-03-19 | Merck Sharp & Dohme Corp. | Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease |
US20060014790A1 (en) * | 2004-01-21 | 2006-01-19 | Varghese John | Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors |
US7968571B2 (en) | 2004-04-20 | 2011-06-28 | Merck, Sharp & Dohme, Corp. | 2,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's Disease |
CN1942457A (zh) | 2004-04-20 | 2007-04-04 | 默克公司 | 作为β-促分泌酶抑制剂用于阿尔茨海默氏病的治疗中的1,3,5-取代的苯基衍生化合物 |
WO2005113582A1 (en) * | 2004-05-22 | 2005-12-01 | Boehringer Ingelheim International Gmbh | Substituted ethane-1,2-diamines for the treatment of alzheimer's disease |
CN1968924B (zh) * | 2004-06-15 | 2011-08-03 | 默沙东公司 | 作为β-分泌酶抑制剂用于治疗阿尔茨海默氏病的吡咯烷-3-基化合物 |
EP1866034A1 (en) | 2005-03-30 | 2007-12-19 | Boehringer Ingelheim International GmbH | Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture |
WO2006110668A1 (en) | 2005-04-08 | 2006-10-19 | Comentis, Inc. | Compounds which inhibit beta-secretase activity and methods of use thereof |
JP2009504613A (ja) * | 2005-08-11 | 2009-02-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アルツハイマー病の治療用化合物 |
EP1915339A1 (de) * | 2005-08-11 | 2008-04-30 | Boehringer Ingelheim International GmbH | Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung |
CA2618481A1 (en) * | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Compounds for treating alzheimer's disease |
WO2007017509A1 (de) * | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Verbindungen zur behandlung der alzheimer erkrankung |
US7872009B2 (en) | 2005-11-21 | 2011-01-18 | Amgen Inc. | Beta-Secretase modulators and methods of use |
US7838676B2 (en) * | 2005-11-21 | 2010-11-23 | Amgen Inc. | Beta-secretase modulators and methods of use |
US7745484B2 (en) | 2005-11-21 | 2010-06-29 | Amgen Inc. | Beta-secretase modulators and methods of use |
CA2629402C (en) | 2005-11-21 | 2011-07-26 | Amgen Inc. | Beta-secretase modulators and methods of use |
TW200901991A (en) | 2007-05-25 | 2009-01-16 | Amgen Inc | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
MX2009012608A (es) | 2007-05-25 | 2009-12-07 | Amgen Inc | Compuestos de hidroxietil amina substituidos como moduladores de beta-secretasa y metodos de uso. |
WO2009007300A2 (en) | 2007-07-06 | 2009-01-15 | Boehringer Ingelheim International Gmbh | Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture |
US7803809B2 (en) | 2008-11-12 | 2010-09-28 | Amgen Inc. | Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use |
ES2459195T3 (es) * | 2008-09-11 | 2014-05-08 | Amgen Inc. | Compuestos de anillo espiro-tetracíclico como moduladores de beta-secretasa y métodos de uso |
EP2504315A1 (en) | 2009-11-23 | 2012-10-03 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
US8822485B2 (en) | 2009-11-23 | 2014-09-02 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
US8735384B2 (en) | 2010-01-19 | 2014-05-27 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
JP5584352B2 (ja) | 2010-03-15 | 2014-09-03 | アムジエン・インコーポレーテツド | β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途 |
EP2547685A1 (en) | 2010-03-15 | 2013-01-23 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta - secretase modulators |
WO2012109165A1 (en) | 2011-02-07 | 2012-08-16 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use |
US9296759B2 (en) | 2011-09-21 | 2016-03-29 | Amgen Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
WO2014078314A1 (en) | 2012-11-15 | 2014-05-22 | Amgen Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362912A (en) * | 1989-05-23 | 1994-11-08 | Abbott Laboratories | Process for the preparation of a substituted diaminodiol |
US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5352705A (en) * | 1992-06-26 | 1994-10-04 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
DE69332616T2 (de) * | 1992-12-29 | 2003-11-06 | Abbott Laboratories, Abbott Park | Hemmer der retroviralen Protease |
WO1996040885A2 (en) * | 1995-06-07 | 1996-12-19 | Athena Neurosciences, Inc. | β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION |
AU4329499A (en) * | 1998-07-30 | 2000-02-21 | Warner-Lambert Company | Reduced dipeptide analogues as calcium channel antagonists |
AU5619400A (en) | 1999-06-15 | 2001-01-02 | Elan Pharmaceuticals, Inc. | Statine-derived tetrapeptide inhibitors of beta-secretase |
-
2003
- 2003-01-06 EP EP03703711A patent/EP1458745A2/en not_active Withdrawn
- 2003-01-06 US US10/337,075 patent/US6962934B2/en not_active Expired - Fee Related
- 2003-01-06 AU AU2003206413A patent/AU2003206413A1/en not_active Abandoned
- 2003-01-06 JP JP2003558035A patent/JP2005534614A/ja active Pending
- 2003-01-06 CA CA002472617A patent/CA2472617A1/en not_active Abandoned
- 2003-01-06 BR BRPI0306724-6A patent/BR0306724A/pt not_active IP Right Cessation
- 2003-01-06 WO PCT/US2003/000326 patent/WO2003057721A2/en active Search and Examination
-
2004
- 2004-07-02 MX MXPA04006575A patent/MXPA04006575A/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
AU2003206413A1 (en) | 2003-07-24 |
JP2005534614A (ja) | 2005-11-17 |
EP1458745A2 (en) | 2004-09-22 |
CA2472617A1 (en) | 2003-07-17 |
AU2003206413A8 (en) | 2003-07-24 |
BR0306724A (pt) | 2006-04-11 |
US20030166580A1 (en) | 2003-09-04 |
WO2003057721A2 (en) | 2003-07-17 |
WO2003057721A3 (en) | 2004-03-25 |
US6962934B2 (en) | 2005-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04006575A (es) | Amino carboxamidas sustituidas para el tratamiento de la enfermedad de alzheimer. | |
TW200512195A (en) | Benzamide 2-hydroxy-3-diaminoalkanes | |
MXPA04000328A (es) | Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer. | |
AP2004002952A0 (en) | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds. | |
MXPA04000338A (es) | Diamindioles para tratamiento de enfermedad de alzheimer. | |
TW200505418A (en) | Phenacyl 2-hydroxy-3-diaminoalkanes | |
TW200505828A (en) | Substituted ureas and carbamates useful in the treatment of alzheimer's disease | |
MXPA04002785A (es) | Aminas sustituidas para tratamiento de enfermedad de alzheimer. | |
WO2004022523A3 (en) | 1, 3-diamino-2-hydroxypropane prodrug derivatives | |
MXPA04003245A (es) | Hidroxipropilaminas. | |
MXPA03011521A (es) | Aminadioles para tratamiento de enfermedad de alzheimer. | |
MXPA03011466A (es) | Macrociclos utiles en tratamiento de enfermedades de alzheimer. | |
DE60211746D1 (de) | Aminosäurederivate zur behandlung der alzheimer-krankheit | |
MXPA03011502A (es) | Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer. | |
MXPA04000337A (es) | Amindioles para tratamiento de enfermedad de alzheimer. | |
BR0314180A (pt) | Aminoéteres substituìdos para o tratamento da doença de alzheimer | |
WO2004029019A3 (en) | Compounds for the treatment of alzheimer’s disease | |
WO2002094768A3 (en) | Aza hydroxylated ethyl amine compounds | |
AU2002362008A1 (en) | Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease | |
WO2005042472A3 (en) | Hydroxypropyl amides for the treatment of alzheimer’s disease | |
WO2004037179A3 (en) | Substituted peptides useful in the treatment of alzheimer’s disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |